Clear, independent answers on research peptides — written for the UK.
Evidence-graded compound profiles, vetted vendor reviews, and UK regulatory clarity. No vendor advertising. No hype. Free to read.
Content Pillars
Five places to start.
Whether you're reading your first compound profile or designing your fifth protocol stack — the depth is here.
Compound Education
Evidence-graded profiles for every peptide that matters.
Browse compounds02UK Regulatory Clarity
What's legal, what's grey, and what's changed in 2026.
Read the legal guide03Vendor Reviews
Independent assessments with third-party purity testing.
Compare vendors04Protocol Guidance
Reconstitution, storage, and research protocols — grounded in the published literature.
View protocol library05Blood Work & Monitoring
What to test, when to test, what the numbers mean.
Open the panel guideFeatured Profiles
The most-read compound profiles this month.
Every profile grades its evidence base explicitly — so you always know where you stand.
5-Amino-1MQ
An NNMT inhibitor peptide researched for fat loss and metabolic function
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule peptide derivative that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme implicated in fat cell metabolism and energy regulation. Research is primarily preclinical — cell and animal models show promising effects on fat loss and metabolic markers, but no human clinical trials have been published as of 2025. Researchers discuss it in the context of obesity, metabolic syndrome, and body composition, though the evidence base remains early-stage.
ACE-031
A recombinant ActRIIB-Fc decoy receptor developed as a myostatin inhibitor, discontinued after Phase 2 safety concerns
ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to a human IgG1 Fc domain. It functions as a soluble decoy receptor that binds and neutralises myostatin and other TGF-β superfamily ligands to promote skeletal muscle growth. ACE-031 reached Phase 2 clinical trials in Duchenne muscular dystrophy but was discontinued in 2011 due to safety concerns including epistaxis and telangiectasia. It is not a licensed medicine and is sold for research purposes only.
AHK-Cu
Copper-binding tripeptide with in vitro evidence for hair growth stimulation and wound healing
AHK-Cu (alanyl-histidyl-lysine-copper, also known as copper tripeptide-2) is a copper-binding tripeptide complex studied for its effects on hair follicle growth, skin repair, and wound healing. It has demonstrated stimulatory effects on dermal papilla cells and hair shaft elongation in vitro. Evidence is primarily preclinical, with no large-scale human clinical trials published.
Amycretin
A first-in-class dual GLP-1 and amylin receptor agonist in early clinical development for obesity
Amycretin is a novel unimolecular peptide that acts as a dual agonist of the GLP-1 and amylin receptors, developed by Novo Nordisk for obesity and weight management. Phase 1b/2a clinical trial results have been published in a peer-reviewed journal, representing early-stage evidence of weight loss. Research use only — not a licensed medicine.
AOD-9604
Modified hGH fragment peptide researched for targeted fat metabolism
AOD-9604 is a synthetic 15-amino-acid peptide based on the C-terminal fragment (residues 177–191) of human growth hormone. Developed in the late 1990s by Metabolic Pharmaceuticals, it was designed to replicate the fat-burning (lipolytic) effects of hGH without its effects on blood glucose, tissue growth, or IGF-1. It reached Phase II human clinical trials, making it one of the more clinically researched peptides in the fat-loss category.
Apraglutide
A long-acting GLP-2 receptor agonist for short bowel syndrome with intestinal rehabilitation potential
Apraglutide (formerly FE 203799) is a long-acting glucagon-like peptide-2 (GLP-2) analogue engineered for once-weekly subcutaneous dosing. It is being developed for the treatment of short bowel syndrome with intestinal failure (SBS-IF), a rare condition in which patients depend on parenteral nutrition due to insufficient intestinal absorption. Phase 3 results from the STARS trial demonstrated significant reductions in parenteral nutrition volume requirements. Research use only — not licensed as a medicine in the UK.
The UK Peptide Starter Guide.
A plain-English introduction to research peptides written specifically for UK readers. Covers what they are, how they're classified, the legitimate vendors, the regulatory landscape — and the questions to ask before doing anything.
One welcome email, then the weekly briefing. Unsubscribe in one click. No vendor spam — ever.